Metabolic Syndrome

Metabolic Syndrome

Metabolic syndrome is diagnosed when at least three of five risk factors occur together: a large waist (abdominal obesity), high triglycerides, low high-density lipoprotein (HDL) cholesterol, high blood pressure and high fasting glucose. It affects an estimated one-third of adults in the United States and is closely tied to insulin resistance, chronic low-grade inflammation and visceral fat. People with metabolic syndrome face a much higher risk of type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease and some cancers.

The biology of metabolic syndrome overlaps closely with the pathways retatrutide targets. Excess visceral fat drives insulin resistance, which leads to compensatory high insulin, abnormal lipids and high blood pressure. Retatrutide acts on the GLP-1, GIP and glucagon receptors at once, so it addresses several parts of the syndrome. GLP-1 and GIP receptor activation improves insulin sensitivity and blood sugar control, while glucagon receptor activity increases fat burning in the liver and energy use, going straight at the visceral fat behind the syndrome.

Retatrutide trial data have shown improvements in several metabolic syndrome measures beyond weight, including fasting glucose, HbA1c, triglycerides and blood pressure. These broad benefits suggest triple agonist drugs may treat metabolic syndrome more completely than single-target drugs, possibly reducing the need for a separate medicine for each part of the syndrome.